Adapt Pharma to Offer All U.S. High Schools a Free NARCAN Nasal Spray and Fund School-Based Opioid Overdose Education

Pharma, Limited
(“Adapt Pharma”) today announced two
national programs at the Clinton Health Matters Initiative Activation
Summit to assist in efforts to address the growing risk of opioid
overdose among American high-school students. First, Adapt Pharma will
offer a free carton of NARCAN® (naloxone hydrochloride) Nasal
Spray to all high schools in the United States through the state
departments of education. This program will collaborate with the Clinton
Health Matters Initiative
, an initiative of the Clinton Foundation,
as part of its work to scale naloxone access efforts nationally.

In addition, Adapt Pharma has provided a grant to the National
Association of School Nurses
(NASN) to support their educational
efforts concerning opioid overdose education materials. To learn more click
or call 844-4-NARCAN.

NARCAN Nasal Spray is the only FDA approved, ready-to-use, needle-free
nasal spray version of naloxone hydrochloride, indicated for the
emergency treatment of opioid overdose. It is not a substitute for
emergency medical care. See below for indication and important safety
For multimedia content, please visit

“We understand the crucial role schools can play to change the course of
the opioid overdose epidemic by working with students and families. We
also want every high school in the country to be prepared for an opioid
emergency by having access to a carton of NARCAN Nasal Spray at no
cost,” said Seamus Mulligan, Chairman and CEO of Adapt Pharma.
“We look forward to working with our partners to implement these
initiatives which build on the significant progress being made by
legislators and community groups.”

“We are pleased to encourage public-private collaborations expanding
access to naloxone,” said Rain Henderson, CEO of the Clinton
Health Matters Initiative
. “We are hopeful this effort will
facilitate a dialogue amongst students, educators, health professionals,
and families about the risks of opioid overdose and ensure naloxone is
available in schools that decide to take steps to address opioid
overdose emergencies.”

NASN President Beth Mattey noted that school nurses act as first
responders in the school setting. “We educate our students, families,
and school staff about prescription drug and substance abuse, and help
families seek appropriate treatment and recovery options,” Mattey said.
“Having access to naloxone can save lives and is often the first step
toward recovery. We are taking a proactive approach to address the
possibility of a drug overdose in school.”

Both programs build on Adapt Pharma’s recently announced initiative to
facilitate affordable access to NARCAN Nasal Spray. Earlier this month,
Adapt Pharma, in partnership with the National Association of
Counties, National Governors Association, National League of Cities and
United States Conference of Mayors
, announced it will offer NARCAN
Nasal Spray at a discounted Public Interest Price through the U.S.
Communities Purchasing Alliance
and Premier,
to over 62,000 state and local government agencies. Click
for further details.



NARCAN® (naloxone hydrochloride) Nasal Spray is an opioid antagonist
indicated for the emergency treatment of known or suspected opioid
overdose, as manifested by respiratory and/or central nervous system
depression. NARCAN® Nasal Spray is intended for immediate administration
as emergency therapy in settings where opioids may be present.

NARCAN® Nasal Spray is not a substitute for emergency medical care.


NARCAN® Nasal Spray is contraindicated in patients known to be
hypersensitive to naloxone hydrochloride.

Seek emergency medical assistance immediately after initial use, keeping
the patient under continued surveillance.

Risk of Recurrent Respiratory and CNS Depression:
Due to the duration of action of naloxone relative to the opioid, keep
the patient under continued surveillance and administer repeat doses of
naloxone using a new nasal spray with each dose, as necessary, while
awaiting emergency medical assistance.

Risk of Limited Efficacy with Partial Agonists or
Mixed Agonists/Antagonists
: Reversal of respiratory depression
caused by partial agonists or mixed agonists/antagonists, such as
buprenorphine and pentazocine, may be incomplete. Larger or repeat doses
may be required.

Precipitation of Severe Opioid Withdrawal:
Use in patients who are opioid dependent may precipitate opioid
withdrawal characterized by body aches, diarrhea, increased heart rate
(tachycardia), fever, runny nose, sneezing, goose bumps (piloerection),
sweating, yawning, nausea or vomiting, nervousness, restlessness or
irritability, shivering or trembling, abdominal cramps, weakness, and
increased blood pressure. In neonates, opioid withdrawal may be
life-threatening if not recognized and properly treated and may be
characterized by convulsions, excessive crying, and hyperactive
reflexes. Monitor for the development of opioid withdrawal.

Risk of Cardiovascular (CV) Effects: Abrupt
postoperative reversal of opioid depression may result in adverse CV
effects. These events have primarily occurred in patients who had
pre-existing CV disorders or received other drugs that may have similar
adverse CV effects. Monitor these patients closely in an appropriate
healthcare setting after use of naloxone hydrochloride.

The following adverse reactions were observed in a NARCAN Nasal Spray
clinical study: increased blood pressure, musculoskeletal pain,
headache, nasal dryness, nasal edema, nasal congestion, and nasal

See Instructions for Use and full prescribing information in the use of
this product. Click

To report SUSPECTED ADVERSE REACTIONS, contact Adapt Pharma, Inc. at
1-844-4NARCAN (1-844-462-7226) or FDA at 1-800-FDA-1088 or


Adapt Pharma is a privately-held pharmaceutical company committed to
positively impacting the lives of patients. Adapt Pharma’s strategy is
to identify, evaluate, selectively acquire and enhance the value of late
stage development, and FDA approved, pharmaceutical products. Adapt
Pharma’s company headquarters is in Dublin, Ireland and its U.S.
headquarters is in Radnor, Pennsylvania. For more information, please


U.S. Media:
Christy Maginn,